查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677340

mRNA 疫苗市场按技术类型、给药途径、製造流程、疫苗分类、应用领域、最终用户和分销管道划分 - 2025 年至 2030 年全球预测

mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

mRNA疫苗市场预估2024年价值93.2亿美元，2025年将达104亿美元，复合年增长率为11.86%，到2030年将达到182.8亿美元。

主要市场统计数据
基准年 2024 年 93.2亿美元
预计 2025 年 104亿美元
预测年份 2030 182.8亿美元
复合年增长率（%） 11.86％

mRNA疫苗已成为现代医疗保健领域的突破。尤其是近年来，这项创新治疗类别已迅速从实验技术走向全球疫苗接种的前沿。 mRNA 疫苗的研发历程经过数十年的严格研究，有效地将实验室的突破转化为拯救生命的临床应用。 mRNA 疫苗能够引发强烈的免疫反应，再加上其简化的开发时间表，凸显了其在对抗新发病原体和慢性疾病方面的价值。

mRNA疫苗技术的出现不仅重新定义了传统的疫苗平台，也提供了设计和製造的灵活性。这项发展为个人化医疗方法打开了大门，有可能解决更广泛的感染疾病、遗传疾病甚至肿瘤学难题。透过利用合成的 mRNA 序列，这些疫苗为在新变种和新病原体出现时更快适应铺平了道路。科学和工业领袖目前正在见证这一领域新颖的生化见解与实际临床应用的融合，这正在改变全球公共卫生的动态。

这篇全面的评论深入探讨了 mRNA 疫苗市场的根本方面和策略意义。探索为医疗保健的未来奠定基础的深刻技术创新、关键市场细分、区域和企业趋势。随着决策者面临竞争日益激烈且节奏越来越快的环境，了解这些方面对于充分发挥 mRNA 疫苗技术的潜力至关重要。

变革将重新定义 mRNA 疫苗生态系统

在科学创新、不断变化的监管环境和全球卫生领域日益增长的担忧的推动下，mRNA 疫苗领域正在发生重大变化。核苷修饰的最新突破和脂质奈米颗粒递送系统的改进极大地提高了 mRNA 平台的安全性和有效性。这些进步不仅加速了药物从发现到上市的过程，而且重新定义了製药业的竞争格局。

明确的监管支持和政府措施进一步增强了人们对这些新平台的信心，从而导致公共和私营部门的投资激增。随着各国优先为未来的流行病做好准备，mRNA 疫苗的扩充性和适应性使其成为一个有吸引力的提案。这种动态正在促进学术界、工业界和监管机构之间的合作，为强大的生态系统奠定基础，使创新治疗方法能够快速应对新出现的全球健康威胁。

本节探讨了重新调整传统疫苗策略的多种变化。它主要关注快速原型製作能力、临床试验中的数位整合以及提高的製造效率如何共同推动市场发展。这些转变证明了该行业的韧性及其整合先进技术以满足全球卫生不断变化的需求的能力。

洞察影响产业趋势的关键领域

透过检验影响行业动态的各种细分标准，市场细分揭示了对 mRNA 疫苗市场的细緻了解。分析表明，以技术为导向的细分至关重要，市场正在透过脂质奈米颗粒 (LNP) 系统、裸 mRNA 技术、核苷修饰 mRNA 方法和自扩增 mRNA 平台等平台进行研究。特别是，裸mRNA技术类别探索了基于胜肽的载体和聚合物奈米颗粒的专门用途，强调了对效率和标靶递送的承诺。

此外，管理途径为了解市场动态提供了重要的见解。可吸入 mRNA 疫苗、注射製剂和口服给药系统的开发和分化凸显了人们对以患者为中心的治疗的偏好以及对非侵入性疫苗通讯协定的推动。製造过程对细分策略也做出了重大贡献，研究重点是无细胞合成和试管内转录方法之间的二分法。

疫苗分类透过区分预防性疫苗和治疗性疫苗进一步细化了市场前景。从应用角度来看，市场涵盖了多种治疗需求，包括心血管疾病、遗传疾病——深入探索囊肿纤维化治疗和镰状细胞病的创新方法、针对 COVID-19 和流感等感染疾病的综合策略，肿瘤学也是同样有前景的重点。此外，最终用户细分提供了有关生物技术公司、委外研发机构、製药公司和研究机构的贡献的详细资讯。最后，分销管道细分考虑了医院药房和零售药房的作用，为理解这些疫苗如何到达最终消费者提供了新的见解。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 感染疾病的传播和新病毒的出现正在推动对mRNA疫苗的需求。
      • mRNA疫苗在动物保健领域的拓展具有市场潜力
      • 民众和政府对疫情防范的支持推动了 mRNA 疫苗研发工作
    • 限制因素
      • 错误讯息可能导致大众对新疫苗技术的怀疑，从而阻碍疫苗的接种。
    • 机会
      • 进行教育宣传活动和官民合作关係，宣传 mRNA 疫苗的益处和安全性
      • 政府与私人资助推动mRNA疫苗研发
    • 任务
      • 了解 mRNA 疫苗核准的复杂法规结构
  • 市场区隔分析
    • 技术类型：越来越多地使用能够有效将 mRNA 递送至细胞的脂质奈米颗粒平台
    • 分发管道：采用医院药房储存并及时注射 mRNA 疫苗
  • 波特五力分析
  • PESTEL 分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 mRNA 疫苗市场（依技术类型）

  • 脂质奈米颗粒（LNP）平台
  • 裸露的mRNA技术
    • 肽基载体
    • 聚合物奈米粒子
  • 核苷修饰mRNA技术
  • 自我扩增 mRNA 平台

第七章 mRNA 疫苗市场（依给药途径）

  • 吸入式 mRNA 疫苗
  • 注射型mRNA疫苗
  • 口服给药系统

第 8 章 mRNA 疫苗市场（依製造流程划分）

  • 无细胞合成
  • 体外转录

第九章 mRNA 疫苗市场（依疫苗分类）

  • 预防疫苗
  • 治疗性疫苗

第 10 章 mRNA 疫苗市场（依应用）

  • 心血管疾病
  • 遗传性疾病
    • 囊肿纤维化治疗
    • 镰状细胞疾病 mRNA 方法
  • 感染疾病
    • 2019冠状病毒病疫苗
    • 流感 mRNA 疫苗
  • 肿瘤学

第 11 章 mRNA 疫苗市场（以最终用户划分）

  • 生技公司
  • 受託研究机构
  • 製药公司
  • 研究所

第 12 章 mRNA 疫苗市场（依通路）

  • 医院药房
  • 零售药局

13. 美洲 mRNA 疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

14. 亚太地区 mRNA 疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

15. 欧洲、中东和非洲 mRNA 疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十六章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Acuitas Therapeutics Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca PLC
  • Bavarian Nordic AS
  • BioNTech SE
  • Chongqing Zhifei Biological Products Co.,Ltd.
  • CureVac NV
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Ethris GmbH
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • Vertex Pharmaceuticals Incorporated
Product Code: MRR-2C19BD4C39D3

The mRNA Vaccines Market was valued at USD 9.32 billion in 2024 and is projected to grow to USD 10.40 billion in 2025, with a CAGR of 11.86%, reaching USD 18.28 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 9.32 billion
Estimated Year [2025] USD 10.40 billion
Forecast Year [2030] USD 18.28 billion
CAGR (%) 11.86%

mRNA vaccines have emerged as a groundbreaking force within modern healthcare. This innovative therapeutic category has rapidly transitioned from experimental technology to the forefront of global immunization efforts, especially in recent years. The journey of mRNA vaccines is characterized by decades of rigorous research that has effectively translated laboratory breakthroughs into life-saving clinical applications. Their ability to elicit robust immune responses combined with a streamlined development timeline underscores their value in combating both emergent pathogens and chronic diseases.

The advent of mRNA vaccine technology not only redefines traditional vaccine platforms but also introduces a level of flexibility in design and manufacturing. This evolution has opened doors to personalized medical approaches, increasing the potential to address a wider array of infectious diseases, genetic disorders, and even oncological challenges. By leveraging synthetic mRNA sequences, these vaccines pave the way for quicker adaptations when new variants or novel pathogens arise. The scientific community and industry leaders are now witnessing the confluence of novel biochemical insights and practical clinical applications in a field that is transforming global public health dynamics.

In this comprehensive review, we delve into the fundamental aspects and strategic implications of the mRNA vaccine market. The discussion will explore the profound technological innovations, critical market segmentations, and regional as well as corporate trends that are setting the stage for future healthcare developments. As decision-makers navigate an increasingly competitive and fast-paced environment, understanding these dimensions is key to leveraging the full potential of mRNA vaccine technology.

Transformative Shifts Redefining the mRNA Vaccine Ecosystem

The landscape of mRNA vaccines has experienced transformative shifts driven by scientific innovation, regulatory evolution, and a heightened sense of urgency within the global health arena. Recent breakthroughs in nucleoside modification and the refinement of lipid nanoparticle delivery systems have dramatically improved the safety and efficacy of mRNA platforms. These advancements have not only accelerated the pathway from discovery to market but also redefined the competitive environment in the pharmaceutical industry.

Clear regulatory endorsements and government initiatives have further bolstered confidence in these novel platforms, leading to a surge in both public and private investment. As nations prioritize preparedness against future pandemics, the scalable and adaptive nature of mRNA vaccines becomes an attractive proposition. This dynamic is fostering collaboration among academia, industry, and regulatory bodies, laying the groundwork for a robust ecosystem where innovative therapies can quickly respond to emergent global health threats.

This section explores the multiple layers of change that have reoriented traditional vaccine strategies. Emphasis is placed on how rapid prototyping capabilities, digital integration in clinical trials, and enhanced manufacturing efficiencies are collectively steering the market. These shifts are a testament to the sector's resilience and its ability to integrate advanced technologies to meet evolving global health demands.

Key Segmentation Insights Shaping Industry Trends

A nuanced understanding of the mRNA vaccine market is evident when one examines the varied segmentation criteria that frame industry trends. The analysis reveals that technology-oriented segmentation is pivotal, where the market is examined through platforms such as lipid nanoparticle (LNP) systems, naked mRNA technologies, nucleoside-modified mRNA approaches, and self-amplifying mRNA platforms. Specifically, the category of naked mRNA technologies delves deeper into the specialized use of peptide-based carriers and polymeric nanoparticles, underscoring a commitment to both efficiency and targeted delivery.

Additionally, the route of administration provides critical insights into market dynamics. The development and differentiation among inhalable mRNA vaccines, injectable formulations, and oral delivery systems highlight the evolving preferences for patient-centric treatments and the drive towards non-invasive vaccination protocols. Manufacturing processes also contribute significantly to the segmentation strategy, with studies focusing on the dichotomy between cell-free synthesis and in vitro transcription methods, each presenting distinct advantages in terms of scalability and cost-effectiveness.

Vaccine classification further refines market perspectives by distinguishing between preventive and therapeutic vaccines. When viewed through the lens of application areas, the market spans a diverse range of therapeutic needs including cardiovascular disorders, genetic diseases-with in-depth explorations into cystic fibrosis treatments and innovative approaches towards sickle cell disease-and comprehensive strategies against infectious diseases like COVID-19 and influenza; oncology remains an equally promising focus. Furthermore, end-user segmentation elaborates on the contributions of biotechnology firms, contract research organizations, pharmaceutical companies, and research institutes. Lastly, the distribution channel segmentation, examining the roles of both hospital pharmacies and retail pharmacies, adds another layer of insight in understanding how these vaccines reach the end consumer.

Based on Technology Type, market is studied across Lipid Nanoparticle (LNP) Platforms, Naked mRNA Technologies, Nucleoside-Modified mRNA Technologies, and Self-Amplifying mRNA Platforms. The Naked mRNA Technologies is further studied across Peptide-Based Carriers and Polymeric Nanoparticles.

Based on Route of Administration, market is studied across Inhalable mRNA Vaccines, Injectable mRNA Vaccines, and Oral Delivery System.

Based on Manufacturing Process, market is studied across Cell-Free Synthesis and In Vitro Transcription.

Based on Vaccine Classification, market is studied across Preventive Vaccines and Therapeutic Vaccines.

Based on Application Areas, market is studied across Cardiovascular Disorders, Genetic Disorders, Infectious Diseases, and Oncology. The Genetic Disorders is further studied across Cystic Fibrosis Treatments and Sickle Cell Disease mRNA Approaches. The Infectious Diseases is further studied across COVID-19 Vaccines and Influenza mRNA Vaccines.

Based on End-User, market is studied across Biotechnology Firms, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes.

Based on Distribution Channel, market is studied across Hospital Pharmacies and Retail Pharmacies.

Key Regional Dynamics Impacting Market Growth

Regional insights play a crucial role in understanding the geographical influences on the mRNA vaccine market. In the Americas, the landscape is characterized by strong research foundations and a robust network of partnerships, setting the stage for iterative innovation and dynamic market expansions. The mature healthcare infrastructure supports rapid adoption of mRNA vaccine solutions, ensuring that advancements translate effectively into public health outcomes.

The region encompassing Europe, the Middle East, and Africa is marked by a blend of sophisticated regulatory frameworks and dynamic market reforms. This diversity presents unique challenges and opportunities that stimulate investment in localized manufacturing and tailored vaccine formulations. Collaborations between academic institutions and industry stakeholders are particularly significant here, as they foster environments conducive to innovation and strategic market penetration.

In Asia-Pacific, rapid economic growth combined with increasing healthcare investments is catalyzing the adoption of advanced therapeutic solutions. The region demonstrates both flexibility in digital integration and a forward-thinking approach towards novel drug development. The strong emphasis on clinical research and expedited pathways for regulatory approvals is contributing to an ecosystem that is both agile and receptive to transformative therapies. Together, these regional dynamics illustrate a global market where local advancements fuel worldwide progress in mRNA vaccine technology.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Market Movers: Key Company Insights Driving Innovation

The competitive landscape of the mRNA vaccine market is shaped by a consortium of influential companies that are driving both innovation and strategic collaborations. Leading industry players such as Acuitas Therapeutics Inc. and Alnylam Pharmaceuticals, Inc. are at the cutting edge of vaccine delivery system advancements, while Arcturus Therapeutics Holdings Inc. continues to push boundaries with self-amplifying mRNA platforms. AstraZeneca PLC and Bavarian Nordic AS bring substantial resources to the table, ensuring that large-scale production and rapid distribution are seamlessly integrated into market strategies.

Companies like BioNTech SE and CureVac N.V. have significantly advanced the field through pioneering research and agile clinical development pathways. Chongqing Zhifei Biological Products Co.,Ltd. marks another key contributor by leveraging regional expertise to customize vaccine solutions for emerging markets. Furthermore, established pharmaceutical giants including Daiichi Sankyo Company, Limited, Eli Lilly and Company, Ethris GmbH, and GlaxoSmithKline PLC have expanded their interest in mRNA technology, integrating it within broader drug portfolios to respond to a spectrum of therapeutic needs.

Innovators such as Inovio Pharmaceuticals, Inc. and Johnson & Johnson Services, Inc. are complementing these efforts by focusing on fine-tuning delivery mechanisms and clinical efficacy. Meanwhile, Merck & Co., Inc. and Moderna Inc. have cemented their positions as trailblazers with substantial R&D investments and global partnerships. Not to be overlooked, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, and Sanofi S.A. continue to significantly influence market direction through strategic mergers and extensive clinical trials. Companies like Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated are also pivotal, contributing diversified expertise that enriches the competitive landscape and fosters a spirit of relentless innovation.

The report delves into recent significant developments in the mRNA Vaccines Market, highlighting leading vendors and their innovative profiles. These include Acuitas Therapeutics Inc., Alnylam Pharmaceuticals, Inc., Arcturus Therapeutics Holdings Inc., AstraZeneca PLC, Bavarian Nordic AS, BioNTech SE, Chongqing Zhifei Biological Products Co.,Ltd., CureVac N.V., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Ethris GmbH, GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Incorporated. Strategic Recommendations for Industry Stakeholders

Industry stakeholders are encouraged to foster cross-disciplinary collaborations aimed at accelerating technological maturation and expanding market reach. Investment in research and development should be prioritized, with a keen focus on optimizing delivery systems and enhancing the scalability of manufacturing processes. Stakeholders must also adopt data-driven decision-making frameworks that leverage real-time analytics to forecast market trends and adapt to shifting regulatory environments.

A proactive approach in forming strategic alliances with academic research centers and technology innovators can create synergies that drive both clinical success and market penetration. Emphasis on embracing digital transformation, particularly in clinical trial management and patient engagement strategies, is essential for maintaining competitive advantage. By positioning themselves at the nexus of innovation and patient care, industry leaders can ensure their strategies remain both flexible and forward-thinking in an era marked by rapid change.

Conclusion: Reflecting on the mRNA Vaccine Market's Future Prospects

In summary, the mRNA vaccine market is positioned at a pivotal juncture, where technological breakthroughs and strategic global collaborations are converging to redefine healthcare solutions. The evolution from traditional vaccine platforms to advanced mRNA technologies illustrates a market driven by innovation, adaptability, and a relentless pursuit of precision medicine.

The synthesis of diverse segmentation insights not only unveils detailed market nuances but also highlights the critical role that regional dynamics and key corporate players play in shaping the industry. As the market continues to expand, the alignment of technological innovation with regulatory and commercial strategies will be instrumental in determining long-term success and global impact.

Ultimately, the future of mRNA vaccines is bright, with extensive opportunities emerging for growth, enhanced public health outcomes, and the democratization of advanced therapeutic solutions across diverse populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of infectious diseases and emerging viral outbreaks spur demand for mRNA vaccines
      • 5.1.1.2. Expansion of mRNA vaccine in animal health sectors is set to market potential
      • 5.1.1.3. Public and governmental support for pandemic preparedness pushes forward mRNA vaccine initiatives
    • 5.1.2. Restraints
      • 5.1.2.1. Public skepticism towards new vaccine technologies, by misinformation, could impede uptake.
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing educational campaigns and public-private partnerships to promote mRNA vaccine benefits and safety
      • 5.1.3.2. Governmental and private funding to advance mRNA vaccine research and development
    • 5.1.4. Challenges
      • 5.1.4.1. Understanding the complex regulatory frameworks for mRNA vaccine approvals
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Technology Type: Growing use of lipid nanoparticle platforms for their ability to deliver mRNA into cells effectively
    • 5.2.2. Distribution Channel: Adoption of hospital pharmacies for storing and timely administering mRNA vaccines
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. mRNA Vaccines Market, by Technology Type

  • 6.1. Introduction
  • 6.2. Lipid Nanoparticle (LNP) Platforms
  • 6.3. Naked mRNA Technologies
    • 6.3.1. Peptide-Based Carriers
    • 6.3.2. Polymeric Nanoparticles
  • 6.4. Nucleoside-Modified mRNA Technologies
  • 6.5. Self-Amplifying mRNA Platforms

7. mRNA Vaccines Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhalable mRNA Vaccines
  • 7.3. Injectable mRNA Vaccines
  • 7.4. Oral Delivery System

8. mRNA Vaccines Market, by Manufacturing Process

  • 8.1. Introduction
  • 8.2. Cell-Free Synthesis
  • 8.3. In Vitro Transcription

9. mRNA Vaccines Market, by Vaccine Classification

  • 9.1. Introduction
  • 9.2. Preventive Vaccines
  • 9.3. Therapeutic Vaccines

10. mRNA Vaccines Market, by Application Areas

  • 10.1. Introduction
  • 10.2. Cardiovascular Disorders
  • 10.3. Genetic Disorders
    • 10.3.1. Cystic Fibrosis Treatments
    • 10.3.2. Sickle Cell Disease mRNA Approaches
  • 10.4. Infectious Diseases
    • 10.4.1. COVID-19 Vaccines
    • 10.4.2. Influenza mRNA Vaccines
  • 10.5. Oncology

11. mRNA Vaccines Market, by End-User

  • 11.1. Introduction
  • 11.2. Biotechnology Firms
  • 11.3. Contract Research Organizations
  • 11.4. Pharmaceutical Companies
  • 11.5. Research Institutes

12. mRNA Vaccines Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacies
  • 12.3. Retail Pharmacies

13. Americas mRNA Vaccines Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific mRNA Vaccines Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa mRNA Vaccines Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Pfizer and BioNTech secure FDA approval for tailored Omicron KP.2 COVID-19 vaccine
    • 16.3.2. BioNTech and CEPI joined hands to enhance Africa's mRNA vaccine landscape with innovative research and local manufacturing
    • 16.3.3. Moderna revealed late-stage trial advancements with progress in the evolution of mRNA vaccine technology
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Acuitas Therapeutics Inc.
  • 2. Alnylam Pharmaceuticals, Inc.
  • 3. Arcturus Therapeutics Holdings Inc.
  • 4. AstraZeneca PLC
  • 5. Bavarian Nordic AS
  • 6. BioNTech SE
  • 7. Chongqing Zhifei Biological Products Co.,Ltd.
  • 8. CureVac N.V.
  • 9. Daiichi Sankyo Company, Limited
  • 10. Eli Lilly and Company
  • 11. Ethris GmbH
  • 12. GlaxoSmithKline PLC
  • 13. Inovio Pharmaceuticals, Inc.
  • 14. Johnson & Johnson Services, Inc.
  • 15. Merck & Co., Inc.
  • 16. Moderna Inc.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Regeneron Pharmaceuticals, Inc.
  • 20. Roche Holding AG
  • 21. Sanofi S.A.
  • 22. Sinovac Biotech Ltd.
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Thermo Fisher Scientific Inc.
  • 25. Vertex Pharmaceuticals Incorporated

LIST OF FIGURES

  • FIGURE 1. MRNA VACCINES MARKET MULTI-CURRENCY
  • FIGURE 2. MRNA VACCINES MARKET MULTI-LANGUAGE
  • FIGURE 3. MRNA VACCINES MARKET RESEARCH PROCESS
  • FIGURE 4. MRNA VACCINES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MRNA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 21. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 25. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 30. MRNA VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 31. MRNA VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MRNA VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MRNA VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MRNA VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MRNA VACCINES MARKET SIZE, BY LIPID NANOPARTICLE (LNP) PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MRNA VACCINES MARKET SIZE, BY PEPTIDE-BASED CARRIERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MRNA VACCINES MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MRNA VACCINES MARKET SIZE, BY NUCLEOSIDE-MODIFIED MRNA TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MRNA VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MRNA VACCINES MARKET SIZE, BY INHALABLE MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MRNA VACCINES MARKET SIZE, BY INJECTABLE MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MRNA VACCINES MARKET SIZE, BY ORAL DELIVERY SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MRNA VACCINES MARKET SIZE, BY CELL-FREE SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MRNA VACCINES MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MRNA VACCINES MARKET SIZE, BY PREVENTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MRNA VACCINES MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MRNA VACCINES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MRNA VACCINES MARKET SIZE, BY CYSTIC FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MRNA VACCINES MARKET SIZE, BY SICKLE CELL DISEASE MRNA APPROACHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MRNA VACCINES MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MRNA VACCINES MARKET SIZE, BY INFLUENZA MRNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MRNA VACCINES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MRNA VACCINES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MRNA VACCINES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MRNA VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MRNA VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MRNA VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MRNA VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES MRNA VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 248. DENMARK MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. DENMARK MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 250. DENMARK MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. DENMARK MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 252. DENMARK MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 253. DENMARK MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 254. DENMARK MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. EGYPT MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. EGYPT MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 260. EGYPT MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. EGYPT MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 262. EGYPT MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 263. EGYPT MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 264. EGYPT MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. FINLAND MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. FINLAND MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 270. FINLAND MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. FINLAND MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 272. FINLAND MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 273. FINLAND MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 274. FINLAND MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. FRANCE MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. FRANCE MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 280. FRANCE MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. FRANCE MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 282. FRANCE MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 283. FRANCE MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 284. FRANCE MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 288. GERMANY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. GERMANY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 290. GERMANY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 291. GERMANY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 292. GERMANY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 293. GERMANY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 294. GERMANY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 298. ISRAEL MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. ISRAEL MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 300. ISRAEL MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 301. ISRAEL MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 302. ISRAEL MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 303. ISRAEL MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 304. ISRAEL MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. ITALY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. ITALY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 310. ITALY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 311. ITALY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 312. ITALY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 313. ITALY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 314. ITALY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 318. NETHERLANDS MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. NETHERLANDS MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 320. NETHERLANDS MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 321. NETHERLANDS MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 322. NETHERLANDS MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 323. NETHERLANDS MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 324. NETHERLANDS MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 328. NIGERIA MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. NIGERIA MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 330. NIGERIA MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 331. NIGERIA MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 332. NIGERIA MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 333. NIGERIA MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 334. NIGERIA MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA MRNA VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA MRNA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 338. NORWAY MRNA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 339. NORWAY MRNA VACCINES MARKET SIZE, BY NAKED MRNA TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 340. NORWAY MRNA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 341. NORWAY MRNA VACCINES MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
  • TABLE 342. NORWAY MRNA VACCINES MARKET SIZE, BY VACCINE CLASSIFICATION, 2018-2030 (USD MILLION)
  • TABLE 343. NORWAY MRNA VACCINES MARKET SIZE, BY APPLICATION AREAS, 2018-2030 (USD MILLION)
  • TABLE 344. NORWAY MRNA VACCINES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY MRNA VACCINES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY MRNA VACCINES MARKET SIZ